Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients

Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients

Background: Generally, little is known about prognostic factors in bladder cancer patients under 40 years of age. We therefore performed a retrospective study to identify prognostic factors in these younger bladder cancer patients. Methods: We collected clinicopathological data on bladder cancer pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mierxiati Abudurexiti, Jie Ma, Yao Li, Chuanyi Hu, Zhikang Cai, Zhong Wang, Ning Jiang
Formato:	Artículo
Lenguaje:	English
Publicado:	MDPI AG 2022-01-01
Colección:	Current Oncology
Materias:	bladder cancer 40 years prognostic factors survival
Acceso en línea:	https://www.mdpi.com/1718-7729/29/2/52

Ejemplares similares

Identification of inflammation related gene signatures for bladder cancer prognosis prediction
por: Yonggui Xiao, et al.
Publicado: (2024-11-01)

Identification and Validation of an Annexin-Related Prognostic Signature and Therapeutic Targets for Bladder Cancer: Integrative Analysis
por: Xitong Yao, et al.
Publicado: (2022-02-01)

Prosthetic shoulder arthroplasty in patients 40 years or younger: outcomes stratified by diagnosis and surgery
por: Samer S. Hasan, et al.
Publicado: (2022-12-01)

Landscape of the intratumroal microenvironment in bladder cancer: Implications for prognosis and immunotherapy
por: Zichen Bian, et al.
Publicado: (2023-01-01)

Elevated expression of ANTXR1 gene in tumors is a poor prognostic biomarker for patients with bladder cancer
por: L. S. Franco, et al.
Publicado: (2025-01-01)

Prognostic role of prognostic nutritional index in patients with bladder cancer: a systematic review and meta-analysis
por: Jing Sun, et al.
Publicado: (2025-01-01)

Association between radiotherapy and prognosis in patients with small cell carcinoma of the bladder undergoing bladder-sparing surgery
por: Fuchao Liang, et al.
Publicado: (2023-10-01)

Unveiling Bladder Cancer Prognostic Insights by Integrating Patient-Matched Sample and CpG Methylation Analysis
por: Chanbyeol Kim, et al.
Publicado: (2024-07-01)

A sialyltransferases-related gene signature serves as a potential predictor of prognosis and therapeutic response for bladder cancer
por: Penglong Cao, et al.
Publicado: (2023-11-01)

Exploration and validation of a novel reactive oxygen species–related signature for predicting the prognosis and chemotherapy response of patients with bladder cancer
por: Yulei Li, et al.
Publicado: (2024-12-01)

Prognostic evaluation of non-muscle invasive bladder cancer with P-CRP and its nomogram
por: Junyun Wu, et al.
Publicado: (2025-02-01)

Construction and validation of a metabolism-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer
por: Chong Shen, et al.
Publicado: (2023-10-01)

Identification and validation of a signature based on myofibroblastic cancer-associated fibroblast marker genes for predicting prognosis, immune infiltration, and therapeutic response in bladder cancer
por: Ruize Qin, et al.
Publicado: (2024-05-01)

A basement membrane-related signature for prognosis and immunotherapy benefit in bladder cancer based on machine learning
por: Yunuo Zhang, et al.
Publicado: (2024-10-01)

Integrating oxidative-stress biomarkers into a precision oncology risk-stratification model for bladder cancer prognosis and therapy
por: Jianxu Huang, et al.
Publicado: (2024-09-01)

Prognostic Value of Bladder Involvement in the Outcome of Upper Tract Urothelial Carcinoma
por: Sara Meireles, et al.
Publicado: (2023-01-01)

Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis
por: Feng Li, et al.
Publicado: (2024-02-01)

Identification and construction of prognostic clusters and risk-prognosis model based on aging-immune related genes in bladder cancer
por: Nihao Cao, et al.
Publicado: (2024-12-01)

Preliminary study on the role of the CSMD2 gene in bladder cancer
por: Zhijun Yao, et al.
Publicado: (2024-01-01)

An analysis of disease burden of bladder cancer in China from 1990 to 2017
por: Hao ZI, et al.
Publicado: (2020-10-01)

CXCR6 expression predicts prognosis and immunotherapeutic benefit in muscle-invasive bladder cancer
por: Xiaolin Lu, et al.
Publicado: (2024-11-01)

CXCL10 could be a prognostic and immunological biomarker in bladder cancer
por: Tao Yin, et al.
Publicado: (2024-05-01)

Effect of unfolded protein response on the immune infiltration and prognosis of transitional cell bladder cancer
por: Xiaokai Yan, et al.
Publicado: (2021-01-01)

Urinary Metabolic Markers of Bladder Cancer: A Reflection of the Tumor or the Response of the Body?
por: Greta Petrella, et al.
Publicado: (2021-10-01)

Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma
por: Lizhu Chen, et al.
Publicado: (2023-11-01)

YKL-40 promotes invasion and metastasis of bladder cancer by regulating epithelial mesenchymal transition
por: Hailong Hao, et al.
Publicado: (2021-01-01)

Construction and verification of a prognostic model for bladder cancer based on disulfidptosis-related angiogenesis genes
por: Zhihao Zhou, et al.
Publicado: (2025-02-01)

One year Outcomes of Patients with ST-Segment Elevation Myocardial Infarction
por: Reza Heidari Moghaddam, et al.
Publicado: (2024-06-01)

Exosomes: Toward a potential application in bladder cancer diagnosis and treatment
por: Xiaowei Wei, et al.
Publicado: (2024-02-01)

Leveraging programmed cell death signature to predict clinical outcome and immunotherapy benefits in postoperative bladder cancer
por: Yifan Wang, et al.
Publicado: (2024-10-01)

NEOADJUVANT CHEMOTHERAPY WITH RADICAL CYSTECTOMY IN THE TREATMENT OF MUSCLE-INVASIVE BLADDER CANCER
por: N. S. Nurgaliev, et al.
Publicado: (2016-10-01)

Relationship between bladder cancer and polymorphisms of OX40 (rs17568) and OX40L (rs1234313) genes in a Turkish population
por: Osman Bilen, et al.
Publicado: (2023-03-01)

Bladder Preservation With Transurethral Tumor Resection and Intravesical BCG Instillation in Superficial Muscle-Invasive Bladder Cancer: A 10-Year Follow-up
por: Dong Gyun Kim, et al.
Publicado: (2023-03-01)

Outcomes of intravesical Bacillus Calmette-Guerin in patients with non-muscle invasive bladder cancer: a retrospective study in Australia
por: Chamodi Pillippu Hewa, et al.
Publicado: (2024-02-01)

The predictive value of PFKFB3 in bladder cancer prognosis
por: Dongxu Qiu, et al.
Publicado: (2024-05-01)

Identification and validation of the nicotine metabolism-related signature of bladder cancer by bioinformatics and machine learning
por: Yating Zhan, et al.
Publicado: (2024-12-01)

Development of a Molecular-Subtype-Associated Immune Prognostic Signature That Can Be Recognized by MRI Radiomics Features in Bladder Cancer
por: Shenghua Liu, et al.
Publicado: (2023-03-01)

Gastric cancer in patients aged younger and older than 50 years: characteristics of gastric cancer and survival analysis
por: N. V. Kovalenko, et al.
Publicado: (2022-05-01)

Identification of E3 ubiquitin ligase-based molecular subtypes and prognostic signature regarding prognosis and immune landscape in bladder cancer
por: Bo Hu, et al.
Publicado: (2025-02-01)

The opposite association of HRAS and KRAS mutations with clinical variables of bladder cancer
por: M. P. Smal, et al.
Publicado: (2015-12-01)